Are we at the peak of the fill & finish investment cycle?
The last few years have seen an unprecedented wave of investment in liquid fill & finish capacity: COVID vaccines first, then GLP-1, plus a steady shift towards biologics and prefilled syringes. Now the signals are mixed. Some see a plateau, others expect the next wave from US onshoring and new modalities. I'd like to get a clearer picture from the people who actually plan, build and supply these lines. So I've set up a 4-question survey that takes less than a minute:
Where is the investment cycle in liquid fill & finish today?
*
Still accelerating
Close to the peak
Past the peak, slowing down
At or near the bottom
How will annual investment in liquid fill & finish capacity in 2027 compare to 2025?
*
Down more than 20 %
Down 10–20 %
Down 5–10 %
Roughly flat (±5 %)
Up 5–10 %
Up more than 10 %
What are the main reasons for your expectation? (max. 2)
*
Sufficient capacity built in recent years (incl. GLP-1, COVID)
Pricing pressure and cost focus (e.g. US drug pricing)
Uncertainty from tariffs and trade policy
US onshoring of pharma manufacturing
Growth in GLP-1, biologics and new modalities
Shift to prefilled syringes, autoinjectors, home care
Replacement of aging lines / regulatory upgrades (Annex 1)
Andere:
Which best describes your organization?
*
Pharma / biotech manufacturer
CDMO / contract manufacturer
Equipment supplier / system integrator
Consultant / investor / other
Absenden
Should be Empty: